Cargando…
P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431066/ http://dx.doi.org/10.1097/01.HS9.0000970352.00363.07 |
| _version_ | 1785091111253966848 |
|---|---|
| author | Weisel, Katja D’souza, Anita Hurd, David Voorhees, Peter Teipel, Raphael Chung, Alfred Rodriguez, Cesar Tuchman, Sacha Korde, Neha Safah, Hana Bueno, Orlando Feng, Zhongling Rosenberg, Tanya Kumar Pothacamury, Rajvineeth Ross, Jeremy Lee, Shane Jin, Ziyi Talati, Chetasi Kumar, Shaji Vij, Ravi |
| author_facet | Weisel, Katja D’souza, Anita Hurd, David Voorhees, Peter Teipel, Raphael Chung, Alfred Rodriguez, Cesar Tuchman, Sacha Korde, Neha Safah, Hana Bueno, Orlando Feng, Zhongling Rosenberg, Tanya Kumar Pothacamury, Rajvineeth Ross, Jeremy Lee, Shane Jin, Ziyi Talati, Chetasi Kumar, Shaji Vij, Ravi |
| author_sort | Weisel, Katja |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431066 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310662023-08-17 P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Weisel, Katja D’souza, Anita Hurd, David Voorhees, Peter Teipel, Raphael Chung, Alfred Rodriguez, Cesar Tuchman, Sacha Korde, Neha Safah, Hana Bueno, Orlando Feng, Zhongling Rosenberg, Tanya Kumar Pothacamury, Rajvineeth Ross, Jeremy Lee, Shane Jin, Ziyi Talati, Chetasi Kumar, Shaji Vij, Ravi Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431066/ http://dx.doi.org/10.1097/01.HS9.0000970352.00363.07 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Weisel, Katja D’souza, Anita Hurd, David Voorhees, Peter Teipel, Raphael Chung, Alfred Rodriguez, Cesar Tuchman, Sacha Korde, Neha Safah, Hana Bueno, Orlando Feng, Zhongling Rosenberg, Tanya Kumar Pothacamury, Rajvineeth Ross, Jeremy Lee, Shane Jin, Ziyi Talati, Chetasi Kumar, Shaji Vij, Ravi P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | p862: a phase 1 first-in-human monotherapy study of abbv-383, a bcma × cd3 bispecific t-cell–redirecting antibody, in relapsed/refractory multiple myeloma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431066/ http://dx.doi.org/10.1097/01.HS9.0000970352.00363.07 |
| work_keys_str_mv | AT weiselkatja p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT dsouzaanita p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT hurddavid p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT voorheespeter p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT teipelraphael p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT chungalfred p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT rodriguezcesar p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT tuchmansacha p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT kordeneha p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT safahhana p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT buenoorlando p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT fengzhongling p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT rosenbergtanya p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT kumarpothacamuryrajvineeth p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT rossjeremy p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT leeshane p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT jinziyi p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT talatichetasi p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT kumarshaji p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma AT vijravi p862aphase1firstinhumanmonotherapystudyofabbv383abcmacd3bispecifictcellredirectingantibodyinrelapsedrefractorymultiplemyeloma |